Faculty Bibliography

Try a new search

Format these results:

Searched for:

in-biosketch:true

person:carrow01

Total Results:

334

Journal of clinical oncology. 2015:33(15).DOI:

Outcomes of dasatinib plus intensive chemotherapy or stem cell transplant (SCT) for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) on Children's Oncology Group AALL0622. [Meeting Abstract]

Slayton, William Birdsall; Kairalla, John A; Schultz, Kirk R; Devidas, Meenakshi; Helian, Shanjun; Pulsipher, Michael; Chang, Bill H; Carroll, William L; Borowitz, Michael J; Brown, Valerie I; Winick, Naomi J; Carroll, Andrew J; Heerema, Nyla A; Gastier-Foster, Julie M; Wood, Brent L; Mizrahy, Sherri L; Hunger, Stephen
ISI:000358036900009
ISSN: 1527-7755
CID: 1729432
Journal of clinical oncology. 2015:33(15).DOI:

Neurocognitive function of children treated for high-risk B-acute lymphoblastic leukemia (HR-ALL) randomized to Capizzi (CMTX) versus high-dose methotrexate (HDMTX): A report from the Children's Oncology Group (COG). [Meeting Abstract]

Winick, Naomi J; Embry, Leanne M; Hardy, Kristina K; Kairalla, John A; Devidas, Meenakshi; Armstrong, Daniel; Hunger, Stephen; Carroll, William L; Larsen, Eric; Raetz, Elizabeth A; Loh, Mignon L; Noll, Robert
ISI:000358036900005
ISSN: 1527-7755
CID: 1729422
Nature communications. 2015:6.DOI: 10.1038/ncomms7604

Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia

Ma, Xiaotu; Edmonson, Michael; Yergeau, Donald; Muzny, Donna M; Hampton, Oliver A; Rusch, Michael; Song, Guangchun; Easton, John; Harvey, Richard C; Wheeler, David A; Ma, Jing; Doddapaneni, HarshaVardhan; Vadodaria, Bhavin; Wu, Gang; Nagahawatte, Panduka; Carroll, William L; Chen, I-Ming; Gastier-Foster, Julie M; Relling, Mary V; Smith, Malcolm A; Devidas, Meenakshi; Guidry Auvil, Jaime M; Downing, James R; Loh, Mignon L; Willman, Cheryl L; Gerhard, Daniela S; Mullighan, Charles G; Hunger, Stephen P; Zhang, Jinghui
There is incomplete understanding of genetic heterogeneity and clonal evolution during cancer progression. Here we use deep whole-exome sequencing to describe the clonal architecture and evolution of 20 pediatric B-acute lymphoblastic leukaemias from diagnosis to relapse. We show that clonal diversity is comparable at diagnosis and relapse and clonal survival from diagnosis to relapse is not associated with mutation burden. Six pathways were frequently mutated, with NT5C2, CREBBP, WHSC1, TP53, USH2A, NRAS and IKZF1 mutations enriched at relapse. Half of the leukaemias had multiple subclonal mutations in a pathway or gene at diagnosis, but mostly with only one, usually minor clone, surviving therapy to acquire additional mutations and become the relapse founder clone. Relapse-specific mutations in NT5C2 were found in nine cases, with mutations in four cases being in descendants of the relapse founder clone. These results provide important insights into the genetic basis of treatment failure in ALL and have implications for the early detection of mutations driving relapse.
PMCID:4377644
PMID: 25790293
ISSN: 2041-1723
CID: 1520792
Pediatric blood & cancer. 2015:62(3):419-26.DOI: 10.1002/pbc.25322

Intensified chemotherapy without SCT in infant ALL: Results from COG P9407 (Cohort 3)

Dreyer, ZoAnn E; Hilden, Joanne M; Jones, Tamekia L; Devidas, Meenakshi; Winick, Naomi J; Willman, Cheryl L; Harvey, Richard C; Chen, I-Ming; Behm, Fred G; Pullen, Jeanette; Wood, Brent L; Carroll, Andrew J; Heerema, Nyla A; Felix, Carolyn A; Robinson, Blaine; Reaman, Gregory H; Salzer, Wanda L; Hunger, Stephen P; Carroll, William L; Camitta, Bruce M
BACKGROUND: Infants with acute lymphoblastic leukemia (ALL) present with aggressive disease and a poor prognosis. Early relapse within 6-9 months of diagnosis is common. Approximately 75% of infants have MLL-rearranged (MLL-R) ALL with event free survival (EFS) ranging from 20% to 30%. Children's Oncology Group (COG) P9407 used shortened (46 weeks), intensified therapy to address early relapse and poor EFS. PROCEDURE: P9407 therapy was modified three times for induction toxicity resulting in three cohorts of therapy. One hundred forty-seven infants were enrolled in the third cohort. RESULTS: We report an overall 5-year EFS and OS of 42.3 +/- 6% and 52.9 +/- 6.5% respectively. Poor prognostic factors included age /=50,000/mul. For infants 90 days (P < 0.0001). Among infants >90 days of age, 5-year EFS rates were 43.8 +/- 8% for MLL-R versus 69.1 +/- 13.6% for MLL-germline ALL (P < 0.0001). CONCLUSIONS: Age
PMCID:5145261
PMID: 25399948
ISSN: 1545-5009
CID: 1477622
Pediatric blood & cancer. 2015:62(3):414-8.DOI: 10.1002/pbc.25311

Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: a report from the Children's Oncology Group

Salzer, Wanda L; Jones, Tamekia L; Devidas, Meenakshi; Dreyer, ZoAnn E; Gore, Lia; Winick, Naomi J; Sung, Lillian; Raetz, Elizabeth; Loh, Mignon L; Wang, Cindy Y; De Lorenzo, Paola; Valsecchi, Maria Grazia; Pieters, Rob; Carroll, William L; Hunger, Stephen P; Hilden, Joanne M; Brown, Patrick
BACKGROUND:Infants with acute lymphoblastic leukemia (ALL) have a poor prognosis. Intensification of therapy has resulted in fewer relapses but increased early deaths, resulting in failure to improve survival. PROCEDURE/METHODS:AALL0631 is a Phase 3 study for infants (<366 days of age) with newly diagnosed ALL. Induction initially (Cohort 1) consisted of 3 weeks of therapy based on COG P9407. Due to excessive early mortality, induction was amended to a less intensive 5 weeks of therapy based on Interfant-99. Additionally, enhanced supportive care guidelines were incorporated with hospitalization during induction until evidence of marrow recovery and recommendations for prevention/treatment of infections (Cohort 2). RESULTS:Induction mortality was significantly lower for patients in Cohort 2 (2/123, 1.6%) versus Cohort 1 (4/26, 15.4%; P = 0.009). All induction deaths were infection related except one due to progressive disease (Cohort 2). Sterile site infections were lower for patients in Cohort 2 (24/123, 19.5%) versus Cohort 1 (15/26, 57.7%; P = 0.0002), with a significantly lower rate of Gram positive infections during induction for patients in Cohort 2, P = 0.0002. No clinically significant differences in grades 3-5 non-infectious toxicities were observed between the two cohorts. Higher complete response rates were observed at end induction intensification for Cohort 2 (week 9, 94/100, 94%) versus Cohort 1 (week 7, 17/25, 68%; P = 0.0.0012). CONCLUSION/CONCLUSIONS:De-intensification of induction therapy and enhanced supportive care guidelines significantly decreased induction mortality and sterile site infections, without decreasing complete remission rates.
PMCID:4480675
PMID: 25407157
ISSN: 1545-5017
CID: 2927322
Blood. 2015:125(4):680-6.DOI: 10.1182/blood-2014-09-595744

A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults

Perez-Andreu, Virginia; Roberts, Kathryn G; Xu, Heng; Smith, Colton; Zhang, Hui; Yang, Wenjian; Harvey, Richard C; Payne-Turner, Debbie; Devidas, Meenakshi; Cheng, I-Ming; Carroll, William L; Heerema, Nyla A; Carroll, Andrew J; Raetz, Elizabeth A; Gastier-Foster, Julie M; Marcucci, Guido; Bloomfield, Clara D; Mrozek, Krzysztof; Kohlschmidt, Jessica; Stock, Wendy; Kornblau, Steven M; Konopleva, Marina; Paietta, Elisabeth; Rowe, Jacob M; Luger, Selina M; Tallman, Martin S; Dean, Michael; Burchard, Esteban G; Torgerson, Dara G; Yue, Feng; Wang, Yanli; Pui, Ching-Hon; Jeha, Sima; Relling, Mary V; Evans, William E; Gerhard, Daniela S; Loh, Mignon L; Willman, Cheryl L; Hunger, Stephen P; Mullighan, Charles G; Yang, Jun J
Acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYA: 16-39 years) is characterized by distinct presenting features and inferior prognosis compared to pediatric ALL. To better understand the disease etiology in this age group, we performed a genome-wide association study (GWAS) to comprehensively identify inherited genetic variants associated with susceptibility to AYA ALL. In the discovery GWAS, we compared genotype frequency at 635,297 SNPs in 308 AYA ALL cases and 6,661 non-ALL controls by using a logistic regression model with European, African and Native American genetic ancestries as a covariates. SNPs that reached association P
PMCID:4304112
PMID: 25468567
ISSN: 0006-4971
CID: 1371022
Blood. 2015:126(23).DOI:

NT5C2 As a Major Contributor to Thiopurine Resistance at ALL Relapse Via Multiple Mechanisms [Meeting Abstract]

Moriyama, Takaya; Meyer, Julia; Liu, Shuguang; Zhao, Xujie; Ying, Zhaohong; Carroll, William L; Yang, Jun J
ISI:000368019001198
ISSN: 1528-0020
CID: 2019372
Blood. 2015:126(23).DOI:

6-Mercaptopurine (6MP) Intake during Maintenance for Childhood Acute Lymphoblastic Leukemia (ALL) - a Comparison of Self-Report and Electronic Monitoring: A Report from the Children's Oncology Group ( COG) Study AALL03N1 [Meeting Abstract]

Landier, Wendy; Chen, Yanjun; Hageman, Lindsey; Kim, Heeyoung; Bostrom, Bruce C; Casillas, Jacqueline; Dickens, David; Evans, William E; Maloney, Kelly W; Mascarenhas, Leo; Ritchey, Arthur K; Termuhlen, Amanda M; Carroll, William L; Wong, FLennie; Relling, Mary V; Bhatia, Smita
ISI:000368019000146
ISSN: 1528-0020
CID: 2019332
Blood. 2015:126(23).DOI:

Mixed Lineage Leukemia Rearrangements (MLL-R) Are Determinants of High Risk Disease in Homeobox A (HOXA)-deregulated T-Lineage Acute Lymphoblastic Leukemia: A Children's Oncology Group Study [Meeting Abstract]

Matlawska-Wasowska, Ksenia; Kang, Huining; Devidas, Meenakshi; Wen, Ji; Harvey, Richard C; Nickl, Christian C; Ness, Scott; Rusch, Michael; Li, Yongjin; Onozawa, Masahiro; Martinez, Carmen; Wood, Brent L; Asselin, Barbara; Chen, I-Ming L; Roberts, Kathryn G; Baruchel, Andre; Soulier, Jean; Dombret, Herve; Zhang, Jinghui; Larson, Richard S; Raetz, Elizabeth; Carroll, William L; Winick, Naomi J; Aplan, Peter D; Loh, Mignon L; Mullighan, Charles G; Hunger, Stephen P; Heerema, Nyla A; Carroll, Andrew J; Dunsmore, Kimberly P; Winter, Stuart S
ISI:000368019002131
ISSN: 1528-0020
CID: 2019422
Cancer research. 2015:75.DOI: 10.1158/1538-7445.AM2015-4729

Frequency of actionable gene fusions in patients with Philadelphia chromosome-like (Ph-like) B-acute lymphoblastic leukemia (ALL): A retrospective study from the Children's Oncology Group (COG) [Meeting Abstract]

Reshmi, Shalini C; Harvey, Richard C; Smith, Amy; Chen, I-Ming; Valentine, Marc; Liu, Yu; Li, Yongjin; Zhang, Jinghui; Roberts, Kathryn G; Shao, Ying; Easton, John; Payne-Turner, Debbie; Devidas, Meenakshi; Heerema, Nyla; Carroll, Andrew J; Raetz, Elizabeth A; Borowitz, Michael J; Wood, Brent L; Angiolillo, Anne L; Burke, Michael M; Salzer, Wanda L; Zweidler-McKay, Patrick A; Rabin, Karen R; Carroll, William L; Loh, Mignon L; Hunger, Stephen P; Mullighan, Charles G; Willman, Cheryl L; Gastier-Foster, Julie M
ISI:000371597104357
ISSN: 1538-7445
CID: 2064532